MoonLake (MLTX) Insider Exchange: 48,978 Class A Issued; 48,978 Class C Cancelled
Rhea-AI Filing Summary
Kristian Reich, Chief Scientific Officer and director of MoonLake Immunotherapeutics (MLTX), executed an equity exchange on 09/02/2025. He surrendered 1,456 common shares of MoonLake AG in exchange for 48,978 Class A ordinary shares of the issuer, and as part of the transaction 48,978 Class C ordinary shares were automatically cancelled for no consideration. The filing discloses that 10,000 MoonLake AG shares held by the reporting person remain subject to a reverse-vesting schedule that completes on January 18, 2026. The filing also states that JeruCON Beratungsgesellschaft mbH owns 2,974,551 Class A ordinary shares, of which Dr. Reich may be deemed an indirect beneficial owner.
Positive
- Conversion completed: 1,456 MoonLake AG shares exchanged for 48,978 Class A ordinary shares as documented
- Class C cancellation: 48,978 Class C ordinary shares were automatically cancelled for no consideration
Negative
- Reverse-vesting condition: 10,000 MoonLake AG shares remain subject to vesting that completes on January 18, 2026, limiting immediate transferability
- No cash proceeds disclosed: Transaction was an exchange with no sale proceeds reported (no liquidity event shown)
Insights
TL;DR: Insider exchanged shares and automatic cancellation of Class C shares occurred; certain shares remain subject to reverse-vesting through 2026.
The Form 4 documents an equity conversion by a senior executive rather than an open-market sale, with 48,978 Class C shares cancelled upon exchange for Class A shares. The presence of a reverse-vesting schedule on 10,000 second-leaver shares indicates ongoing retention conditions through January 18, 2026. The filing clarifies indirect ownership through JeruCON Beratungsgesellschaft mbH, which is relevant to beneficial ownership aggregates under Section 16.
TL;DR: Transaction is a share conversion with cancellation mechanics; no cash proceeds or open-market trades reported.
The reported activity is a structural equity conversion: 1,456 MoonLake AG shares were exchanged for 48,978 Class A ordinary shares, and corresponding Class C shares were cancelled for no consideration. There is no disclosed sale, purchase price, or market transaction proceeds in this Form 4. The filing was executed by an attorney-in-fact and lists potential indirect beneficial ownership via JeruCON totaling 2,974,551 Class A shares, which investors may use to reconcile insider ownership totals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class A ordinary shares, par value $0.0001 per share | 48,978 | $0.00 | -- |
| Disposition | Class C ordinary shares, par value $0.0001 per share | 48,978 | $0.00 | -- |
| holding | Class A ordinary shares, par value $0.0001 per share | -- | -- | -- |
| Conversion | Common shares, par value CHF 0.10 per share, of MoonLake AG | 1,456 | $0.00 | -- |
Footnotes (1)
- On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest. (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
